<DOC>
	<DOCNO>NCT00356928</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cyclophosphamide , work different way stop growth abnormal blood cell , either kill cell stop divide . Giving cyclophosphamide together donor lymphocyte treat laboratory may effective treatment myelodysplastic syndrome myeloproliferative disorder . PURPOSE : This clinical trial study best dose donor lymphocyte give together cyclophosphamide treat patient myelodysplastic syndrome myeloproliferative disorder .</brief_summary>
	<brief_title>Cyclophosphamide Plus Transplantation Partially HLA-mismatched , CD8+ T Cell-depleted Peripheral Blood Cells Patients With Myelodysplastic Syndrome , Refractory Acute Myeloid Leukemia , Refractory Lymphoma Myeloproliferative Disorders</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose allogeneic CD8-positive T-cell-depleted , haploidentical donor lymphocytes give cyclophosphamide patient myelodysplastic syndrome myeloproliferative disorder . OUTLINE : Patients receive cyclophosphamide day 1 2 . Patients undergo infusion allogeneic T-cell deplete donor lymphocyte day 3 . Cohorts patient receive escalate dos CD8-positive T-cell-depleted haploidentical donor lymphocytes maximum tolerate dose determine . PROJECTED ACCRUAL : A total 44 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Myelodysplastic syndrome ( MDS ) International Prognostic Scoring System ( IPSS ) score ≥ intermediate2 Chronic myelomonocytic leukemia Acute myeloid leukemia arise MDS Must fail ineligible intolerant treatment azacitidine Patients normal marrow cytogenetics isolate 5q abnormality must fail ineligible intolerant treatment lenalidomide Patients HLADR15positive must fail ineligible pharmacologic immunosuppression ( e.g. , antithymocyte globulin , cyclosporine , steroid ) No presence cytotoxic antibody donor lymphocytes No HLAidentical donor available OR ineligible HLAidentical allogeneic bone marrow transplantation HLA partially mismatch ( haploidentical ) relate donor available Firstdegree relate donor , include halfsiblings first cousins Inherited recombinant haplotype parent allow donor share ≥ 1 HLA antigen HLAA , B , DR locus PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 OR Karnofsky PS 80100 % Bilirubin &lt; 3.0 mg/dL AST ALT ≤ 4 time upper limit normal Creatinine &lt; 3.0 mg/dL LVEF &gt; 35 % PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior transfusion donor At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) radiotherapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
</DOC>